Login to Your Account

PTC ‘Pax’ cash coffers, Macrogenics, too: $109M each in priced offerings

By Randy Osborne
Staff Writer

Thursday, February 13, 2014

Though winter storm Pax put the freeze on the Northeast U.S. after ravaging the South, biotech funders seemed to feel little of the chill, with PTC Therapeutics Inc. and Macrogenics Inc. pricing public offerings for $109.7 million and $109.5 million, respectively.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription